| Trial ID: | L0113 |
| Source ID: | NCT06430684
|
| Associated Drug: |
Empagliflozin 10 Mg
|
| Title: |
Feasibility Trial of Sodium-GLucose CoTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
|
| Acronym: |
SGLT2I-IN-KIDS
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases|Pediatric Kidney Disease
|
| Interventions: |
DRUG: Empagliflozin 10 MG
|
| Outcome Measures: |
Primary: Percentage of participants who complete all study procedures, Compared to the number recruited, how many participants complete the study, 4 years | Secondary: Systolic Blood Pressure, In-clinic systolic blood pressure, 3 months|Serum N-terminal pro-brain natruetic peptide (NT-proBNP), 3 months|Urine Albumin to Creatinine Ratio (UACr), 3 months|Left Atrial Reservoir Strain, Measuring using echocardiography, 3 months
|
| Sponsor/Collaborators: |
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-08-23
|
| Completion Date: |
2026-06-01
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-14
|
| Locations: |
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT06430684
|
